Imagion Biosystems
Tracked across 2 events · 19 articles · First seen Jun 09, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Imagion Biosystems secured AU$3.75 million in new capital, which will fund the commencement of a Phase 2 clinical trial for its MagSense imaging agent in HER2-positive breast cancer. This funding is crucial for advancing its molecular MRI technology.
Jun 25, 2026 · 6 articles
Business
Impact: Imagion Biosystems is presenting at the 93rd Emerging Growth Conference to engage with investors and showcase its company, products, and services.
Jun 09, 2026 · 13 articles
ERGEN INTELLIGENCE
Track Imagion Biosystems live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard